Gardasil efficacy data

The summary of product characteristics (SPC) for Gardasil (human papillomavirus [HPV] types 6, 11, 16 and 18) has been updated.

The new SPC includes information on studies that showed Gardasil has cross-protective efficacy in preventing precancerous cervical lesions due to 10 other HPV types, including type 31.

HPV 31 is related to HPV 16 and is the second most common HPV type in Europe causing precancerous cervical lesions after type 16.

Gardasil is licensed for the prevention of premalignant genital lesions (cervical, vulvar and vaginal), cervical cancer and external genital warts (condyloma acuminata) causally related to HPV types 6, 11, 16 and 18.

View Gardasil drug record

Further information: Sanofi Pasteur MSD

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Drug shortages - live tracker

Drug shortages - live tracker

Check on the latest drug supply issues with MIMS' shortages...

Novel MS drug gains NICE approval

Novel MS drug gains NICE approval

New NICE guidance recommends ocrelizumab (Ocrevus)...

Emollients, Potential Skin Sensitisers as Ingredients

Emollients, Potential Skin Sensitisers as Ingredients

Potential sensitising agents in emollient preparations.

NICE recommends new triple therapy option for diabetes

NICE recommends new triple therapy option for diabetes

Ertugliflozin (Steglatro) can now be prescribed routinely...